Sonnet BioTherapeutics: Funding, Investors & Team (Sep 2026)
Sonnet BioTherapeutics is a biotechnology company that focuses on creating innovative biologic drugs using either a single or bispecific mechanism of action. One of their key technologies, called FHAB™ (Fully Human Albumin Binding), allows for the development of targeted biologic drugs by attaching a fully human single-chain antibody fragment (scFv) to human serum albumin (HSA). This attachment enhances the drug's effects by improving its transport and accumulation in target tissues, such as inflammation sites and tumors. Unlike other platforms, Sonnet's FHAB utilizes a fully human sequence with a human glycosylation profile that can be produced using a standard CHO process.
Sonnet BioTherapeutics has raised $24.6M across 3 funding rounds on record, the most recent an undisclosed round of $5.0M announced in Nov 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sonnet BioTherapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Sonnet BioTherapeutics Funding Rounds
Sonnet BioTherapeutics raised $15.0M in an undisclosed round announced in Feb 2023.
8 months later, an undisclosed round of $4.6M was announced in Oct 2023.
1.1 years later, an undisclosed round of $5.0M was announced in Nov 2024.
Sonnet BioTherapeutics Founders and Leadership Team
Contact details for the Sonnet BioTherapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Sonnet BioTherapeutics Funding Compared to Other Biotechnology Startups
Sonnet BioTherapeutics' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sonnet BioTherapeutics in Biotechnology and Princeton
Companies Similar to Sonnet BioTherapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Sonnet BioTherapeutics Funding FAQs
What does Sonnet BioTherapeutics do?
Sonnet BioTherapeutics is a biotechnology company that focuses on creating innovative biologic drugs using either a single or bispecific mechanism of action. One of their key technologies, called FHAB™ (Fully Human Albumin Binding), allows for the development of targeted biologic drugs by attaching a fully human single-chain antibody fragment (scFv) to human serum albumin (HSA). This attachment enhances the drug's effects by improving its transport and accumulation in target tissues, such as inflammation sites and tumors. Unlike other platforms, Sonnet's FHAB utilizes a fully human sequence with a human glycosylation profile that can be produced using a standard CHO process.
How much funding has Sonnet BioTherapeutics raised?
Sonnet BioTherapeutics has raised $24.6M across 3 rounds on record. The most recent is an undisclosed round of $5.0M announced in Nov 2024.
When did Sonnet BioTherapeutics last raise funding?
Sonnet BioTherapeutics' most recent funding round on record is an undisclosed round of $5.0M, announced in Nov 2024.
Who founded Sonnet BioTherapeutics?
FundedIQ lists John K Cini (Founder), Pankaj Mohan (Founder) at Sonnet BioTherapeutics.
Where is Sonnet BioTherapeutics headquartered?
Sonnet BioTherapeutics is based in Princeton, New Jersey, United States.
How many employees does Sonnet BioTherapeutics have?
Sonnet BioTherapeutics is in the 11-50 employee band.
How does Sonnet BioTherapeutics' funding compare to other Biotechnology startups?
Sonnet BioTherapeutics' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Sonnet BioTherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sonnet BioTherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.